Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Renal Cell Carcinoma – Geographic Focus: China – China In-Depth – Renal Cell Carcinoma
The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Johnson & Johnson Innovative Medicine’s Carvykti, have given hope to patients with relapsed/refractory (R/R) non-Hodgkin’s…
Obesity / Overweight – Access & Reimbursement – Access & Reimbursement – Obesity / Overweight (US)
Obesity is a significant public health concern. Although inexpensive phentermine is commonly prescribed for weight management, newer therapies like glucagon-like peptide-1 (GLP-1) receptor agonists…
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Neuropsychiatric Therapies in Alzheimer’s Disease (US)
In 2023, Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation associated with Alzheimer’s disease (AD). Other novel agents are now emerging as potential treatments…
Neuropathic Pain – Current Treatment – Current Treatment: Physician Insights – Neuropathic Pain (US)
The treatment of neuropathic pain involves the use of drugs from several classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…
